Your browser is no longer supported. Please, upgrade your browser.
BEAM Beam Therapeutics Inc. monthly Stock Chart
Beam Therapeutics Inc.
Index- P/E- EPS (ttm)-3.10 Insider Own1.70% Shs Outstand50.09M Perf Week20.60%
Market Cap2.62B Forward P/E- EPS next Y-2.63 Insider Trans0.00% Shs Float48.20M Perf Month31.99%
Income-131.50M PEG- EPS next Q-0.66 Inst Own64.60% Short Float6.40% Perf Quarter91.10%
Sales0.02M P/S109280.41 EPS this Y22.40% Inst Trans39.74% Short Ratio4.77 Perf Half Y82.05%
Book/sh3.99 P/B11.94 EPS next Y12.60% ROA-49.80% Target Price43.00 Perf Year-
Cash/sh3.67 P/C12.97 EPS next 5Y- ROE-107.10% 52W Range13.00 - 45.15 Perf YTD154.19%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High5.56% Beta-
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low266.62% ATR3.11
Employees118 Current Ratio4.40 Sales Q/Q0.00% Oper. Margin- RSI (14)75.25 Volatility7.51% 7.57%
OptionableYes Debt/Eq0.03 EPS Q/Q-40.00% Profit Margin- Rel Volume1.00 Prev Close44.69
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume646.80K Price47.66
Recom1.40 SMA2026.55% SMA5045.76% SMA20089.78% Volume645,142 Change6.65%
Aug-05-20Initiated William Blair Outperform
Mar-02-20Initiated Wedbush Outperform $32
Mar-02-20Initiated JP Morgan Overweight $31
Mar-02-20Initiated Jefferies Buy $32
Mar-02-20Initiated Barclays Overweight $32
Nov-20-20 04:01PM  
Nov-13-20 08:00AM  
Nov-10-20 06:30AM  
Nov-09-20 08:15AM  
Nov-02-20 06:06AM  
Oct-07-20 10:04AM  
Oct-02-20 08:00AM  
Sep-28-20 04:18PM  
Aug-12-20 06:30AM  
Aug-04-20 07:15AM  
Jul-30-20 06:30AM  
Jun-15-20 06:00AM  
May-26-20 06:30AM  
May-18-20 06:21PM  
May-12-20 01:40PM  
May-06-20 10:25AM  
Apr-28-20 04:35PM  
Mar-30-20 06:30AM  
Mar-16-20 07:00AM  
Mar-05-20 01:53PM  
Feb-11-20 07:41AM  
Feb-05-20 07:05PM  
Jan-27-20 07:24AM  
Jan-25-20 05:00AM  
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ciaramella GiuseppePresident & CSOSep 30Option Exercise0.673,7312,5003,731Oct 02 05:49 PM
Burrell Terry-AnnCFOSep 18Option Exercise13.687,30999,9877,309Sep 21 09:08 PM
Evans John M.CEOApr 16Option Exercise1.03115,000118,450993,257Aug 17 09:25 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.